А. A. Мамедова

ORCID: 0000-0002-7296-9190
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Immunotherapy and Biomarkers
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Blood disorders and treatments
  • Blood Pressure and Hypertension Studies
  • Cardiac Imaging and Diagnostics
  • Cardiovascular Function and Risk Factors
  • Abdominal vascular conditions and treatments
  • Healthcare Systems and Public Health
  • Galectins and Cancer Biology
  • Multiple and Secondary Primary Cancers
  • Neutropenia and Cancer Infections
  • Immune Cell Function and Interaction
  • Macrophage Migration Inhibitory Factor
  • Cardiovascular Syncope and Autonomic Disorders
  • Colorectal Cancer Treatments and Studies
  • Immunodeficiency and Autoimmune Disorders
  • Workplace Health and Well-being
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Organ Transplantation Techniques and Outcomes
  • Renal Diseases and Glomerulopathies
  • Transplantation: Methods and Outcomes
  • Mycobacterium research and diagnosis
  • Heart Failure Treatment and Management
  • Liver physiology and pathology

National Medical and Surgical Center named after N.I. Pirogov
2021-2025

V.I.Shumakov Federal Research Center of Transplantology and Artificial Organs
2023-2024

Kazan State Medical University
2024

Ministry of Health of the Russian Federation
2024

Aim. To assess efficacy of netupitant / palonosetron with dexamethasone for chemotherapy‑induced nausea and vomiting in 20 patients multiple myeloma who underwent autologous hematopoietic stem cell transplantation. Materials methods. The inclusion criteria were aged ≥18 years a diagnosis myeloma, eligible transplantation favorable response (according to the International Myeloma working Group after induction therapy). Netupitant was administered at dose 1 capsule (300 mg netupitant; 0.5...

10.17650/1818-8346-2025-20-1-146-153 article EN cc-by Oncohematology 2025-03-21
S. А. Boytsov Yuri P. Burtsev Yunona Khomitskaya Karpov IuA I. K. Kagramyan and 95 more D. F. Morukova P. T. Hondzaeva A. S. Borodin T. A. Zarechneva D. E. Mesheryakov O. G. Tullaeva N. A. Kvasova N. V. Serebryakov A. I. Beketova H. S. Matveeva S. N. Livova L. V. Bikeeva И. В. Молчанова O. N. Korneeva M. M. Abu-Aldjadel M. G. Papirina A. V. Kolchurina TEREZA PETRAKOVA E. N. Chistyakova N. V. Hartova N. S. Kucheruk Kamala Rustamova Elizaveta Grigorieva V. L. Fillipov E. J. Baitova N. V. Gavrikova M. V. Hakieva Irina Zinovieva L. N. Mezina M. M. Adamyana G. V. Profatilova E. V. Ustinova G. M. Ivanchenko A. N. Nurieva E. U. Volodenkova F. Z. Zagidova Natālija Pahomova A. U. Ualichamova M. S. Popova S. B. Chrulenko G. M. Orozalieva I. S. Zhalsareva A. U. Hodzaeva A. Z. Kulieva O. P. Pesenko A. V. Kanahina M. S.-A. Baharchieva M. A. Koshrokova I. I. Chugunova L. A. Orlov M. O. Zarubina T. V. Skurtul L. M. Fagradyan O. V. Sabitova Georgi Mihailov E. U. Demianova E. A. Shilina V. B. Nadtochieva E. A. Egorenko A. K. Gusova E. P. Turovceva Daria V. Semenova I. G. Spiridonov E. A. Zolotareva O. V. Grosheva N. N. Kotova EKATERINA EMELIANOVA T. A. Sipilina N. V. Sudareva A. A. Lukovskaia N. N. Redkova E. V. Solodchuk U. S. Belyaeva Y. V. Orlyanskaya M. V. Kotlyarova I. V. Timofeeva N. I. Ryabova A. S. Druzinin R. E. Dubinskaya Anastasia Dmitrieva E. S. Lutikova V. V. Pantiukhova E. V. Mannanova I. E. Dubrovina N. N. Lisic A. U. Novoshenina R. P. Shafranskaya A. U. Laverichev E. L. Averianova А. A. Мамедова Nataliya Alekseeva U. V. Zhukova С. Г. Андреева I. V. Levshun R. V. Tatarskaya

Combination antihypertensive therapy is required by most patients to achieve guideline-recommended blood pressure (BP) goals. This study assessed the effectiveness and tolerability of bisoprolol/perindopril (Bis/Per) single-pill combination (SPC) in Russian with hypertension coronary artery disease (CAD) treated routine clinical practice. STYLE (NCT03730116) was an open-label, uncontrolled, prospective observational conducted who were already receiving Bis/Per SPC, switched SPC from Bis or...

10.1007/s12325-021-01754-2 article EN cc-by-nc Advances in Therapy 2021-05-15

Background. Checkpoint inhibitors contribute to improving the treatment outcomes in patients with relapsed/refractory classical Hodgkin's lymphoma (cHL). The paper describes first generalized experience pembrolizumab-induc-ing cHL immunotherapy Russia. hallmark of study is a long follow-up period. Aim. To retrospectively assess efficacy and safety pem-brolizumab-inducing cHL. Materials & Methods. enrolled 14 patients: 3 men 11 women aged 24-57 years (median 33 years). Pembrolizumab 200...

10.21320/2500-2139-2021-14-1-53-62 article EN cc-by-nc-sa Clinical oncohematology 2021-01-01

Background: Immunotherapy with checkpoint inhibitors (anti-PD-1) is highly effective in relapsed/refractory (R/R) classical Hodgkin Lymphoma (cHL) and leads to more than 70% overall response rate. However, long-term progression-free survival rate not sufficient. Consolidation ASCT after anti-PD-1 could be a very promising option even among previously chemorefractory patients. Nevertheless, there enough experience about the safety feasibility of context possible immune-related adverse events...

10.1097/01.hs9.0000847232.50505.64 article EN cc-by-nc-nd HemaSphere 2022-06-01

One of the most pressing issues in contemporary transplantology is ongoing search for less invasive methods that would identify potential complications recipients solid organ transplants may encounter. Profibrogenic factor galectin-3 (Gal-3) a marker such complications. It presumed it be involved regulatory processes both physiological and pathological conditions; Gal-3 particular importance diseases associated with chronic inflammation fibrosis. Objective: to assess predictive significance...

10.15825/1995-1191-2024-3-159-167 article EN cc-by Russian Journal of Transplantology and Artificial Organs 2024-05-03

Most epidemiological studies are devoted to studying the prevalence of risk factors (RFs) for cardiovascular diseases (CVD) in general population, but this problem has not been sufficiently studied people working age. Purpose. To study CVD and their relationship with outcomes working-age patients arterial hypertension (AH). Material methods. Data from 13,994 who were observed on an outpatient basis analyzed. The analysis was carried out according following factors: gender, age, body mass...

10.29296/25877305-2024-09-15 article EN Vrach 2024-09-11

BACKGROUND. Over the past years, digital technologies have been increasingly used worldwide for monitoring patient-reported assessment data in real-world clinical practice. Electronic systems allow to automatically assess a patient’s perception of disease and therapy convenient mode, remotely, with obvious savings time resources. AIM. To develop test domestic electronic system health status patients hematologic malignancies based on their quality-of-life data. MATERIALS & METHODS. At...

10.21320/2500-2139-2024-17-4-390-403 article EN Clinical oncohematology 2024-10-01

Federation Clinical outcomes of solid organ transplantation depend on many factors. One the main factors is risk post-transplant complications, which affect allograft and recipient survival. Multifactorial damage in complications search for diagnostic prognostic indicators condition have contributed to study selection a wide range proteomic molecular genetic biomarkers, shown be effective transplantation. The use biomarkers opens up additional possibilities assessing their early diagnosis....

10.15825/1995-1191-2023-2-148-157 article EN cc-by Russian Journal of Transplantology and Artificial Organs 2023-07-16

Aim . To study the efficacy and safety of combined immunochemotherapy according to DHAp protocol + nivolumab in patients with refractory/relapsed classical Hodgkin's lymphoma before autologous hematopoietic stem cell transplantation. Materials methods The consisted 2 phases: 1 st - immunotherapy (2 injections as monotherapy at a dose 240 mg/day 14 days interval); nd (14 after administration nivolumab): 480 on day combination chemotherapy protocol, 4 cycles total. effectiveness therapy was...

10.17650/1818-8346-2022-17-3-40-47 article EN cc-by Oncohematology 2022-07-19

Aim. To assess the efficacy of a long-acting form granulocyte colony-stimulating factor (G-CSF) empegfilgrastim in primary prevention neutropenia patients with advanced stages classical Hodgkin lymphoma (cHL) who received intensive chemotherapy reduced inter-cycle interval under protocol “LKh-Rossiya-1”.
 Materials & Methods. The study enrolled 35 newly diagnosed cHL. All had (IIB X/Е and III/IV) disease. They were treated at NI Pirogov National Medical Surgical Center from March...

10.21320/2500-2139-2023-16-4-370-379 article EN Clinical oncohematology 2023-09-29

Development of minimally invasive diagnosis techniques for complications in recipients, based on analysis the levels molecular and genetic biomarkers, is an urgent task facing modern transplantology. Transforming growth factor beta 1 (TGF-β1), which has multiple effects body, among potential indicators complications. Objective: to assess diagnostic significance serum TGF-β1 kidney recipients with graft dysfunction. Materials methods. The study included 129 aged 17 68 years 35 healthy...

10.15825/1995-1191-2023-4-130-138 article EN cc-by Russian Journal of Transplantology and Artificial Organs 2023-11-14

Проблема изучения перинатальной патологии нервной системы у новорожденных детей различного гестационного возраста остается актуальной, что обусловлено прогрессирующим ростом частоты церебральных нарушений - 80% (Барашнев Ю. И., 2005; Баранов А. А., 2008). Перинатальные факторы, вызывающие развитие гипоксически-ишемической энцефалопатии приводят в дальнейшем к неврологическим и соматическим расстройствам, инвалидизации, социальной дизадаптации, придает данной проблеме медико-социальную...

10.28942/nnj.v1i3.202 article RU NATIONAL JOURNAL OF NEUROLOGY 2019-01-15

When evaluating the effect of therapy for malignant neoplasms with inhibitors CTLA-4, PD-1 and PD-L1, phenomenon pseudoprogression may occur. Pseudoprogression is an increase in volume tumor tissue due to immunocompetent cells (lymphocytes, macrophages) mobilized into focus under action immunotherapy. As antitumor lymphocytes macrophages realized, decreases or disappears over time. occurs varying frequency various types cancer. It also matter which immune checkpoint used treat a solid...

10.26442/18151434.2021.3.200952 article EN Journal of Modern Oncology 2021-11-19
Coming Soon ...